2-47475112-C-G
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 6P and 1B. PM1PP3_StrongBP6
The NM_000251.3(MSH2):c.1847C>G(p.Pro616Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000322 in 1,613,962 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000251.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MSH2 | NM_000251.3 | c.1847C>G | p.Pro616Arg | missense_variant | 12/16 | ENST00000233146.7 | NP_000242.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MSH2 | ENST00000233146.7 | c.1847C>G | p.Pro616Arg | missense_variant | 12/16 | 1 | NM_000251.3 | ENSP00000233146 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152140Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000676 AC: 17AN: 251478Hom.: 0 AF XY: 0.0000368 AC XY: 5AN XY: 135910
GnomAD4 exome AF: 0.0000328 AC: 48AN: 1461822Hom.: 0 Cov.: 33 AF XY: 0.0000275 AC XY: 20AN XY: 727214
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152140Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74332
ClinVar
Submissions by phenotype
not provided Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Dec 21, 2023 | Observed in individuals with colon, breast, or other cancers (PMID: 25980754, 26580448, 28944238, 29212164, 28135145, 28828701, 30217226, 32957588, 31265121, 33471991); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Published functional studies suggest a neutral effect: mismatch repair activity comparable to wild-type (PMID: 33357406); This variant is associated with the following publications: (PMID: 23729658, 32957588, 26046367, 25980754, 26580448, 28526081, 28828701, 28944238, 28135145, 29212164, 30217226, 32090079, 31265121, 9774676, 18822302, 18822303, 21120944, 33471991, 34326862, 33357406) - |
Likely benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 20, 2023 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Aug 08, 2023 | In the published literature, this variant has been reported in an individual affected with a Lynch syndrome–associated cancer and/or polyps (PMID: 25980754 (2015)), colorectal cancer (PMIDs: 28135145 (2017), 28944238 (2017), 29212164 (2017)), breast/ovarian cancer (PMIDs: 28828701 (2017), 31265121 (2020), 32957588 (2020)), and acute lymphoblastic leukemia (PMID: 26580448 (2015)). The results from one indirect functional study indicated that this variant likely retains DNA mismatch repair activity in HAP1 cells, while discordant results were observed in a different cell line (PMID: 33357406 (2021)). The frequency of this variant in the general population, 0.00031 (11/35438 chromosomes in Latino/Admixed American subpopulation (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is higher than would generally be expected for pathogenic variants in this gene. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. - |
Hereditary cancer-predisposing syndrome Uncertain:1Benign:2
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 15, 2021 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Likely benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | May 11, 2020 | - - |
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | Nov 12, 2021 | - - |
not specified Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Nov 26, 2019 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 06, 2023 | Variant summary: MSH2 c.1847C>G (p.Pro616Arg) results in a non-conservative amino acid change located in the DNA mismatch repair protein MutS, core (IPR007696) domain of the encoded protein sequence. Three of three in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 6.8e-05 in 251478 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in MSH2 causing Hereditary Nonpolyposis Colorectal Cancer (6.8e-05 vs 0.00057), allowing no conclusion about variant significance. c.1847C>G has been reported in the literature in patients with colorectal cancer and other cancer phenotypes (examples: Raskin_2017, Yurgelun_2017, DeRychke_2017, etc). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Nonpolyposis Colorectal Cancer. Co-occurrences with other pathogenic variants have been reported (MSH2 large deletion, Cheng_2017; RAD51C c.934C>T, p.Arg312Trp, Germani_2020), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Ten clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments (likely benign/benign, n=3, VUS n=7). Based on the evidence outlined above, the variant was classified as likely benign. - |
Lynch syndrome 1 Uncertain:1Benign:1
Benign, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Mar 21, 2023 | This variant is considered benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. Homozygosity for this variant has been confirmed in one or more individuals lacking clinical features consistent with gene-specific recessive disease, indicating that this variant is unlikely to be pathogenic. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Oct 18, 2016 | - - |
Carcinoma of colon Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The MSH2 p.Pro616Arg variant was identified in 4 of 5226 proband chromosomes (frequency: 0.001; Cheng 2015, Yurgelun 2015, Zhang 2015) with Lynch syndrome-related cancers or colorectal polyps. The variant was identified in dbSNP (ID: rs587779965 as With Uncertain significance allele), ClinVar (5x as a variant of uncertain significance), and UMD-LSDB (1x). The variant was identified in control databases in 17 of 277206 chromosomes at a frequency of 0.00006 (Genome Aggregation Database Feb 27, 2017). Breakdown of the observations by population include: African in 1 of 24034 chromosomes (freq: 0.00004), Latino in 12 of 34418 chromosomes (freq: 0.0003), and European Non-Finnish in 4 of 126704 chromosomes (freq: 0.00003), while the variant was not observed in the Other, Ashkenazi Jewish, East Asian, Finnish, or South Asian populations. The p.Pro616 residue is well conserved in mammals and other organisms and 5 of 5 computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the p.Pro616Arg variant may impact the protein; however, this information is not reliably predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and 5 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information, clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
MSH2-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 05, 2024 | The MSH2 c.1847C>G variant is predicted to result in the amino acid substitution p.Pro616Arg. This variant has been reported in individuals with colorectal cancer and/or suspected Lynch syndrome (Yurgelun et al. 2017. PubMed ID: 28135145; Raskin et al. 2017. PubMed ID: 29212164; Table S2, Yurgelun et al. 2015. PubMed ID: 25980754; Table S4a, Zhang et al. 2015. PubMed ID: 26580448). This variant is reported in 0.031% of alleles in individuals of Latino descent in gnomAD and has conflicting interpretations regarding its pathogenicity in ClinVar, ranging from benign to uncertain (https://www.ncbi.nlm.nih.gov/clinvar/variation/127636/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Lynch syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Mendelics | Jul 02, 2018 | - - |
Hereditary nonpolyposis colorectal neoplasms Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 06, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at